HYPAQUE-CYSTO
LOE ApproachingNDAURETHRALSOLUTIONPriority Review
Approved
Aug 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE-CYSTO is a urethral solution diagnostic agent approved in 1969 by GE HealthCare for cystourethography procedures. The product is a contrast medium used to visualize the bladder and urethra during diagnostic imaging studies. It represents a legacy diagnostic imaging category with limited modern clinical innovation.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%) signals a mature product with likely declining team investment and minimal growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product currently shows zero linked job openings, indicating minimal active hiring and limited career growth trajectory. Working on HYPAQUE-CYSTO would involve supporting a mature, stable diagnostic product with declining market relevance rather than building a growing franchise.
Brand ManagerField Sales Representative
Worked on HYPAQUE-CYSTO at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.